drugset / Trial / NCT05801783
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
Phase 0
Unknown
10 enrolled
Shanghai Yunying Medical Technology
Shanghai 10th People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
10 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety, tolerability, and efficacy of the recombinant herpes simplex virus I, R130 in patients with relapsed/refractory ovarian cancer.
Timeline
- Start
- 2022-12-02
- Primary completion
- 2024-12-02
- Completion
- 2025-12-02